Generic Biosimilar Medicines Association

Making Medicines Affordable

  • Home
  • About GBMA
    • Contact us
    • GBMA Members
    • Guiding principles
    • Code of Practice
      • Code Complaint Committee
      • Historical Event Reporting
      • Annual Review
        • 2011
        • 2012
        • 2013
        • 2014
        • 2015
        • 2016
        • 2017
        • 2018
        • 2019
        • 2020
        • 2021
      • Lodging a complaint
    • Media Enquiries
    • Our Objectives
    • Links
  • Advocacy
    • New 5-year Strategic Agreement
    • Extended Strategic Agreement
    • Generic Medicines Working Group (GMWG)
    • Submissions
  • Generics
    • Facts and Fallacies
    • Key Figures on Generic Medicines
    • What is a Generic Medicine?
    • Bioequivalence Explained
  • Biosimilars
    • IGBA Global Biosimilars Week
    • GBMA Position on Biosimilars
      • Impact of Biosimilars
      • Switching
      • Pharmacy Substitution
      • Regulation
      • Awareness and Uptake
      • Naming
    • Key Figures on Biosimilars
  • Topics
    • IGBA
    • Price Disclosure
    • Intellectual Property
    • International Trade Agreements
  • News
    • News 2022
    • News 2021
    • News 2020
    • News 2019
    • News 2018
    • News 2017
    • News 2016
    • News 2015
    • News 2014
  • GBMA Education
  • COVID-19 Virus
    • COVID-19 Virus: The Facts
You are here: Home / Generic Medicines Facts / Topics / IGBA

IGBA

GBMA is an associate member of the International Generic and Biosimilar Medicines Association (IGBA)

httpss://www.youtube.com/watch?v=36XeApjBG-o

 

Originally called the International Generic Pharmaceutical Alliance (IGPA), IGBA was founded in March 1997 as an international network of generic medicines associations. The name of the organization was changed in September 2015 to the International Generic and Biosimilar Medicines Association to reflect the evolving nature of the industry.

IGBA is committed to promoting generic and biosimilar medicines, and exchanging information worldwide. IGBA consists of the following associations:

  • Canadian Generic Pharmaceutical Association (CGPA-Canada)
  • Medicines for Europe (Europe)
  • Generic Pharmaceutical Association (GPhA-USA)
  • Japan Generic Medicines Association  (JGA-Japan)
  • Jordanian Association of Pharmaceutical Manufacturers (JAPM-Jordan)
  • National Association of Pharmaceutical Manufacturers (NAPM-South Africa)
  • Taiwan Generic Pharmaceutical Association (TGPA-Taiwan)
  • In addition, the generic medicines associations of Australia, Brazil and Mexico are Associate Members

Through its constituent member associations, the IGBA maintains constant dialogue with the ICH, WHO, WTO, WIPO and other international organizations.

IGBA members share a set of common principles:

Access to affordable quality medicines 

  • We believe that seeking to improve access to affordable quality medicines worldwide and promote the quality, safety and efficacy of generic medicines is of utmost importance.

Ensure timely access for patients 

  • We all know how difficult it is to strike a balance between patent protection and free competition, which is why achieving balanced intellectual property rights in our sector will ensure timely access for patients to our products.

Global harmonisation of regulations relating to quality 

  • A top priority is to promote the global harmonisation of regulations relating to the quality of generic products, especially ensuring strict adherence to bioequivalence standards.

Improving regulatory and legal expertise 

  • We have worked very hard to provide guidance to international organisations and national governments to improve their regulatory and legal expertise relating to the manufacture, registration and marketing of high quality generic medicines, and promotion of uniform and effective GMP standards and quality controls.

Prevent the production and trade of counterfeit versions 

  • We are concerned with the counterfeiting of medicines, which is a criminal act that puts the health and life of patients in jeopardy. As an alliance, we are fighting in favour of strict and effective regulatory controls to prevent the production and trade of counterfeit versions of all medicines and their APIs.

 

Our Members

logo_ACCORD
logo_ACCORD
Organon logo
Organon logo
Juno
Juno
Sandoz logo
Sandoz logo
Viatris
Viatris
Arrow logo
Arrow logo
apotex
apotex
Celltrion Healthcare
Celltrion Healthcare
Fresnius Kabi
Fresnius Kabi
Fresnius Kabi
commercial_eyes
commercial_eyes
sinapse
sinapse

Generic Medicines: The Facts

Generic Medicines Facts

Generic medicines are quality medicines at affordable prices. Ask your doctor to prescribe a generic medicine, or ask for a generic medicine next time you take your prescription to the pharmacy. … More…

The promise of Biosimilars

Biosimilars

https://youtu.be/sBDur7xa084   Biosimilars provide a unique opportunity to help manage the growing costs of biological medicines on the PBS. They offer therapeutically equivalent and … More…

Peak body for affordable medicines welcomes the announcement of Mark Butler as the new Minister for Health and Aged Care – Prioritising patients is the shared mission

June 1, 2022

Tuesday May 31, 2022 Canberra, ACT The announcement of Australia’s new Health … More...

2022 Biosimilar Awareness Week: 30 May – 3 June

May 30, 2022

Marking a new dawn in medicine choice and affordability #BiosimilarAwarenessWeek2022 Monday May … More...

Health Minister, Greg Hunt MP and Shadow Health Minister, Mark Butler MP both applaud the role of the GBMA Strategic Agreement for the security of the supply of vital medicines

April 1, 2022

Friday March 1, 2022 Canberra, ACT In … More…

© 2022 Generic Medicines Industry Association Pty Ltd | Site Map | Contact Us